.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Many adults aged 60 years or older take thyroid hormone medication for life. However, long-term use is not always necessary for everyone. A recent study investigated levothyroxine discontinuation in elderly patients. Researchers conducted a prospective trial involving 370 participants in the Netherlands. They aimed to determine who could safely stop treatment while maintaining normal thyroid function. These findings provide vital evidence for clinicians managing thyroid health in older populations.
Specifically, the study reported that 25.7% of participants successfully stopped taking levothyroxine. These individuals maintained stable thyrotropin (TSH) and free thyroxine (fT4) levels for one year. Notably, the success rate jumped to 63.6% for those taking a dose of 50 µg/day or lower. Furthermore, thyroid-related quality of life did not change significantly after stopping the drug. This suggests that many patients do not experience negative symptoms when they deprescribe thyroid hormones. Consequently, doctors should consider evaluating the need for ongoing therapy in older adults.
Moreover, the protocol involved a stepwise dose reduction rather than immediate cessation. This cautious approach ensures patient safety and allows for regular laboratory monitoring. Additionally, the study included community-dwelling adults who had stable dosages for at least one year. These results highlight a significant opportunity to reduce polypharmacy and avoid potential overtreatment. Therefore, clinicians should prioritize TSH evaluation for those on low-dose supplementation. Identifying suitable candidates for discontinuation can improve overall geriatric care and health outcomes.
No, discontinuation is not suitable for every patient. This study focused on adults 60 or older with stable low doses and TSH levels below 10 mIU/L. Always consult a physician before changing or stopping your dosage.
Patients on a levothyroxine dose of 50 µg/day or lower have a much higher success rate. In this trial, over 60% of those on low doses successfully stopped the medication without negative effects.
Disclaimer: This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A prospective study reveals that 25.7% of adults aged 60 or older can successfully discontinue levothyroxine, particularly those on low dosages (≤50 µg/d)....
5 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
